Evidence map›Paper›PMID 35177857›Full record

ArticleNature medicine2022

Influenza virus infection history shapes antibody responses to influenza vaccination.

Maria Auladell, Hoang Vu Mai Phuong, Le Thi Quynh Mai, Yeu-Yang Tseng, Louise Carolan, Sam Wilks, Pham Quang Thai, David Price, Nguyen Thanh Duong, Nguyen Le Khang Hang and 18 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 9 institutions in 6 countries.

Maria AuladellDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-9179-3568
Hoang Vu Mai PhuongNational Institute of Hygiene and Epidemiology, Ha Noi, Vietnam.
Le Thi Quynh MaiNational Institute of Hygiene and Epidemiology, Ha Noi, Vietnam.
Yeu-Yang TsengWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Louise CarolanWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Sam WilksCentre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK.
Pham Quang ThaiNational Institute of Hygiene and Epidemiology, Ha Noi, Vietnam.ORCID http://orcid.org/0000-0002-3796-6162
David PriceCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-0076-3123
Nguyen Thanh DuongHa Nam Centre for Preventive Medicine, Ha Nam, Vietnam.
Nguyen Le Khang HangNational Institute of Hygiene and Epidemiology, Ha Noi, Vietnam.
Le Thi ThanhNational Institute of Hygiene and Epidemiology, Ha Noi, Vietnam.
Nguyen Thi Hong ThuongOxford University Clinical Research Unit, Wellcome Africa Asia Programme, National Hospital of Tropical Diseases, Ha Noi, Vietnam.
Tran Thi Kieu HuongOxford University Clinical Research Unit, Wellcome Africa Asia Programme, National Hospital of Tropical Diseases, Ha Noi, Vietnam.
Nguyen Thi Ngoc DiepOxford University Clinical Research Unit, Wellcome Africa Asia Programme, National Hospital of Tropical Diseases, Ha Noi, Vietnam.
Vu Thi Ngoc BichOxford University Clinical Research Unit, Wellcome Africa Asia Programme, National Hospital of Tropical Diseases, Ha Noi, Vietnam.
Arseniy KhvorovWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Luca HensenDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-8467-8537
Tran Nhu DuongNational Institute of Hygiene and Epidemiology, Ha Noi, Vietnam.
Katherine KedzierskaDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-6141-335X
Dang Duc AnhNational Institute of Hygiene and Epidemiology, Ha Noi, Vietnam.
Heiman WertheimOxford University Clinical Research Unit, Wellcome Africa Asia Programme, National Hospital of Tropical Diseases, Ha Noi, Vietnam.
Scott D BoydStanford University Medical Centre, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0963-044X
Kim L Good-JacobsonDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.ORCID http://orcid.org/0000-0003-1891-7274
Derek SmithCentre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK.
Ian BarrWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Sheena SullivanWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-0856-0294
H Rogier van DoornOxford University Clinical Research Unit, Wellcome Africa Asia Programme, National Hospital of Tropical Diseases, Ha Noi, Vietnam.ORCID http://orcid.org/0000-0002-9807-1821
Annette FoxDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. annette.fox@unimelb.edu.au.ORCID http://orcid.org/0000-0002-0565-7146
National Institute Of Hygiene And Epidemiology · VNThe Royal Melbourne Hospital · AUThe University of Melbourne · AUOxford University Clinical Research Unit · VNUniversity of Cambridge · GBAngkor Hospital for Children · KHAustralian Regenerative Medicine Institute · AURadboud University Nijmegen · NLStanford University · US

Funding

Wellcome Trust 089276/Z/09/ZWellcome Trust 106680/Z/14/Z
6 · The paper itself

Abstract

Studies of successive vaccination suggest that immunological memory against past influenza viruses may limit responses to vaccines containing current strains. The impact of memory induced by prior infection is rarely considered and is difficult to ascertain, because infections are often subclinical. This study investigated influenza vaccination among adults from the Ha Nam cohort (Vietnam), who were purposefully selected to include 72 with and 28 without documented influenza A(H3N2) infection during the preceding 9 years (Australian New Zealand Clinical Trials Registry 12621000110886). The primary outcome was the effect of prior influenza A(H3N2) infection on hemagglutinin-inhibiting antibody responses induced by a locally available influenza vaccine administered in November 2016. Baseline and postvaccination sera were titrated against 40 influenza A(H3N2) strains spanning 1968-2018. At each time point (baseline, day 14 and day 280), geometric mean antibody titers against 2008-2018 strains were higher among participants with recent infection (34 (29-40), 187 (154-227) and 86 (72-103)) than among participants without recent infection (19 (17-22), 91 (64-130) and 38 (30-49)). On days 14 and 280, mean titer rises against 2014-2018 strains were 6.1-fold (5.0- to 7.4-fold) and 2.6-fold (2.2- to 3.1-fold) for participants with recent infection versus 4.8-fold (3.5- to 6.7-fold) and 1.9-fold (1.5- to 2.3-fold) for those without. One of 72 vaccinees with recent infection versus 4 of 28 without developed symptomatic A(H3N2) infection in the season after vaccination (P = 0.021). The range of A(H3N2) viruses recognized by vaccine-induced antibodies was associated with the prior infection strain. These results suggest that recall of immunological memory induced by prior infection enhances antibody responses to inactivated influenza vaccine and is important to attain protective antibody titers.

Indexed as

Influenza, HumanInfluenza VaccinesAdultAntibodies, ViralAntibody FormationAustraliaHemagglutination Inhibition TestsHumansInfluenza A Virus, H3N2 SubtypeVaccinationVaccines, InactivatedAntibodies, ViralInfluenza VaccinesVaccines, Inactivated

Identifiers

PMID35177857
OpenAlexW4212798531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.